ajbhu - you asked nicely and I shall answer:
Please note that I am impervious to mocking and take your request seriously.
By the way, I am not an expert.
This is just for starters and I am sure that other posters would like to add to it.
2) Come clean on all R&D related items including, but not limited to, the current applicable agreement(s) with QUT. Put a stop referring to patents and/or know-how the company does not own.
Example 1: Come clean on what IP is owned/attributable to the company and what to QUT.
Who, as a company employee, was involved in Government/State Research grants?
Have there been any benefits, in IP terms, attributable to the company?
Example 2: The company does not own any patents as implied below:
13/01/2009 - VitroGro Patent Granted in USA http://www.asx.com.au/asxpdf/20090113/pdf/31fjz60q3g52r8.pdf
.........
12/10/2010 Third VitroGro Patent Granted in Australia http://www.asx.com.au/asxpdf/20101012/pdf/31t1t44wcxkq76.pdf
3) Put the company in an extended trading halt and renegotiate with QUT the IP transfer and R&D agreements. This is an absolute must and should take precedence over all other following items.
If no agreement can be reached put the company into administration (as a last resort).
4) Sack the R&D Manager and use the Patent lawyer’s she has been using in a more direct fashion.
5) Sack (or reduce to the absolute necessary minimum) the European sales team and ask our European partners – Quintiles, Movianto, …. - to fill the void (if there is one to fill).
6) Amend the Company Equity Option Plan. Make it applicable only for company employee’s (minimum 12+ month employment). Stop rewarding non-company employees/researchers/students/etc. for work that is not beneficial for the company. Remember: Tissue Therapies is not a charity organization.
And so on and on and on ……
And last, but not least, Fix-up the website and stop being on the economic side of the truth.
In this day and age of Google it is advisable to stay in close touch with the truth.
Sadly, Prof. Harding and Prod Baxter have been removed as Scientific Advisors.
Do not regurgitate over-and over-again an outdated trial.
TIS Price at posting:
8.9¢ Sentiment: Hold Disclosure: Held